Opportunity Information: Apply for PAR 27 112
Apply for PAR 27 112
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2026-09-01.
- Applicants must submit their applications by 2028-06-12.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed) is a National Institute on Aging (NIA), National Institutes of Health (NIH) career development grant meant for early-stage clinician-scientists who are already showing momentum as independent investigators and emerging leaders in aging-related research. The central purpose is to accelerate both research development and leadership growth, not only within the applicant's clinical specialty but also in the broader field of aging research. In practice, the award supports a structured, mentored career development period that helps promising clinician-scientists strengthen their research program, expand their expertise in aging, and build the leadership skills needed to influence clinical care and scientific directions in aging.
A key feature of this K76 opportunity is that it targets a more advanced early-career profile than many other mentored K awards. Applicants are expected to have already secured competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level, or to have otherwise used faculty-level research support to establish an independent line of investigation. This means the program is not designed for individuals who are still primarily dependent on a mentor's funding or who are only beginning to define their niche. Instead, NIA is looking for clinician-scientists who can demonstrate they have begun to stand up an independent research trajectory and who can point to tangible evidence of leadership, whether in clinical innovation, research leadership, program development, or related domains.
The "Clinical Trial Not Allowed" designation is a major boundary for what can be proposed. Under this Notice of Funding Opportunity (NOFO), the applicant cannot propose a project in which they will lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial as the primary trial leader. The intent is to keep the supported research focused on projects that do not require the applicant to serve as the responsible trial director. That said, the NOFO does allow applicants to include a clinically relevant research experience that is connected to a clinical trial, as long as the clinical trial itself is led by a mentor or co-mentor. In other words, the candidate can gain experience working with clinical trial infrastructure, data, or trial-related research questions, but they cannot be the person leading the trial as an independent clinical trialist within the K76 project.
In terms of who can apply, the eligible applicant organizations are broad and reflect typical NIH institutional eligibility. Eligible applicants include various levels of U.S. government entities (state, county, city or township, special district), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, Native American tribal governments (federally recognized) and other eligible tribal organizations, public housing authorities/Indian housing authorities, and a wide range of nonprofit and for-profit organizations (including small businesses, and for-profits other than small businesses). The opportunity is listed as a discretionary grant in the health area and is associated with CFDA number 93.866. While many organization types may be eligible to submit, the program expectations around being an early-stage clinician-scientist with faculty-level research support effectively narrow the practical candidate pool to settings where such clinician-scientists are typically appointed and supported, such as academic medical centers, research universities, and research-focused health systems.
There are strict limits on foreign involvement. Non-U.S. entities (foreign organizations) are not eligible to apply. In addition, non-U.S. components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. The practical takeaway is that the work supported under this NOFO must be conducted without foreign components, and applicants should plan the research and career development activities accordingly, keeping the project fully within allowable U.S.-based institutional and project structures.
Administratively, this opportunity is run by NIH (specifically NIA). The funding opportunity number is PAR-27-112, and the title clearly signals both the Beeson program identity and the clinical trial restriction. The original closing date listed is 2028-06-12, indicating a multi-year window during which applications may be accepted according to NIH receipt cycles and the NOFO's stated due dates. The excerpted listing does not specify an award ceiling or expected number of awards, which is common in some NIH postings because budgets and award counts can vary by fiscal year appropriations, program priorities, and application volume; applicants typically confirm current budget guidance and any institute-specific expectations directly in the NOFO text.
Overall, the Beeson K76 is best understood as a mentored, leadership-forward career development award for clinician-scientists who are already transitioning into independence and who have demonstrated early leadership and the capacity to drive an aging-related research program. It is structured to help those candidates expand research skills, deepen aging expertise, and grow into broader leadership roles, while explicitly avoiding proposals where the candidate is leading a clinical trial themselves, even though participation in a mentor-led trial as part of the training and research environment can be included.
Frequently Asked Questions (FAQ)
What is the Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76)?
The Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed) is a National Institute on Aging (NIA), National Institutes of Health (NIH) career development grant for early-stage clinician-scientists. It is designed for individuals who are already showing momentum as independent investigators and emerging leaders in aging-related research, and it supports a structured, mentored career development period focused on both research growth and leadership development in aging.
What is the main purpose of this award?
The central purpose is to accelerate research development and leadership growth. The award aims to help promising clinician-scientists strengthen and expand their research program, deepen expertise in aging, and build leadership skills that can influence clinical care and scientific directions in aging.
Who is this K76 award intended for?
This opportunity targets early-stage clinician-scientists who are already transitioning into independence. Applicants are expected to demonstrate tangible evidence of leadership and to be developing an independent aging-related research trajectory, rather than still being primarily dependent on a mentor's funding or only beginning to define their niche.
How is the K76 different from many other mentored K awards?
A key distinguishing feature is that it targets a more advanced early-career profile than many other mentored K awards. Applicants are expected to have already secured competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level, or to have used faculty-level research support to establish an independent line of investigation.
What does "Clinical Trial Not Allowed" mean for this funding opportunity?
Under this NOFO, the applicant cannot propose a project where they will lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial as the primary trial leader. The supported research must not require the candidate to serve as the responsible trial director within the K76 project.
Can the K76 project include any clinical trial-related activities at all?
Yes. The NOFO allows a clinically relevant research experience connected to a clinical trial, as long as the clinical trial itself is led by a mentor or co-mentor. This means the candidate may gain experience with clinical trial infrastructure, data, or trial-related research questions, but cannot be the primary leader of the clinical trial as part of the K76.
What types of leadership evidence does NIA appear to be looking for?
The opportunity emphasizes emerging leaders. Evidence of leadership can include leadership in clinical innovation, research leadership, program development, or related domains, along with clear signs the applicant is building an independent research trajectory in aging-related research.
What kinds of organizations are eligible to apply?
Eligible applicant organizations are broad and include U.S. government entities (state, county, city or township, special district), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments and other eligible tribal organizations, public housing authorities/Indian housing authorities, and a wide range of nonprofit and for-profit organizations (including small businesses and for-profits other than small businesses).
Even if many organizations are eligible, what kinds of settings are most likely to be practical for applicants?
While many organization types may be eligible to submit, the practical candidate pool is narrowed by program expectations (early-stage clinician-scientist, faculty-level research support, and an emerging independent research program). In practice, this tends to align with academic medical centers, research universities, and research-focused health systems where clinician-scientists commonly hold faculty appointments and have access to research support.
Are foreign organizations eligible to apply?
No. Non-U.S. entities (foreign organizations) are not eligible to apply under this opportunity.
Can a U.S. organization include a foreign component or non-U.S. component in the project?
No. Non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. The work supported under this NOFO must be planned without foreign components and kept within allowable U.S.-based institutional and project structures.
Which agency and institute administer this opportunity?
This opportunity is administered by the National Institutes of Health (NIH), specifically the National Institute on Aging (NIA).
What is the funding opportunity number?
The funding opportunity number is PAR-27-112.
What is the listed closing date for this opportunity?
The original closing date listed is 2028-06-12, indicating a multi-year window during which applications may be accepted according to NIH receipt cycles and the NOFO's stated due dates.
Is this opportunity associated with a CFDA number?
Yes. It is associated with CFDA number 93.866.
What type of grant is this described as?
It is listed as a discretionary grant in the health area.
Does the listing specify an award ceiling or the expected number of awards?
The excerpted listing does not specify an award ceiling or the expected number of awards. This can occur in NIH postings because budgets and award counts may vary by fiscal year appropriations, program priorities, and application volume; applicants typically confirm current budget guidance and institute expectations in the full NOFO text.
What is the overall focus of the supported career development period?
The K76 supports a structured, mentored period intended to help clinician-scientists strengthen their research program, expand expertise in aging, and build leadership skills needed to influence clinical care and scientific directions in aging, while staying within the restriction that the candidate does not lead a clinical trial as part of the award.
Browse more opportunities from the same category: Health
Next opportunity: BJS FY 2026 National Criminal History Improvement Program (NCHIP) Training and Technical Assistance
Previous opportunity: Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 27 112
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 27 112) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: NIGMS Mature Synchrotron Resources (MSR) for Structural Biology (P30 - Clinical Trial Not Allowed) Apply for PAR 27 068 Funding Number: PAR 27 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Long-term health outcomes of people living with spina bifida Apply for CDC RFA DD 26 0222 Funding Number: CDC RFA DD 26 0222 Agency: Centers for Disease Control - NCBDDD Category: Health Funding Amount: $300,000 |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) Apply for RFA AI 27 005 Funding Number: RFA AI 27 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional) Apply for PAR 27 076 Funding Number: PAR 27 076 Agency: National Institutes of Health Category: Health Funding Amount: $499,000 |
| Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed) Apply for RFA DK 27 112 Funding Number: RFA DK 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 27 053 Funding Number: PAR 27 053 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed) Apply for RFA AI 27 014 Funding Number: RFA AI 27 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Trauma Care Readiness and Coordination Cooperative Agreement Apply for EP U3R 26 002 Funding Number: EP U3R 26 002 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $500,000 |
| Improving the Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 002 Funding Number: RD ET RDA 26 002 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
| Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations Apply for CDC RFA DP 27 0023 Funding Number: CDC RFA DP 27 0023 Agency: Centers for Disease Control - NCCDPHP Category: Health Funding Amount: Case Dependent |
| National Indian Health Outreach and Education Apply for HHS 2026 IHS NIHOE 0001 Funding Number: HHS 2026 IHS NIHOE 0001 Agency: Indian Health Service Category: Health Funding Amount: $1,101,311 |
| NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) Apply for PAR 28 072 Funding Number: PAR 28 072 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) Apply for PAR 28 057 Funding Number: PAR 28 057 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) Apply for PAR 28 056 Funding Number: PAR 28 056 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional) Apply for RFA OD 27 009 Funding Number: RFA OD 27 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fiscal Year (FY) 2027 Service Area Competition (SAC) Apply for HRSA 27 005 Funding Number: HRSA 27 005 Agency: Health Resources and Services Administration Category: Health Funding Amount: $10,116,100 |
| IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed) Apply for RFA HG 27 008 Funding Number: RFA HG 27 008 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed) Apply for RFA HG 27 007 Funding Number: RFA HG 27 007 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| NIAMS P30 Centers Program (P30 - Clinical Trial Not Allowed) Apply for RFA AR 28 001 Funding Number: RFA AR 28 001 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed) Apply for RFA RM 27 016 Funding Number: RFA RM 27 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 27 112", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.